This report provides a comprehensive analysis of the global generic nifedipine controlled-release tablets market, focusing on its application in treating hypertension and angina. It examines market dynamics, including key growth drivers and trends, while offering detailed forecasts through 2032 across major regions such as the Americas, APAC, and Europe. The study further explores segmentation by dosage type and application, evaluates competitive landscapes among leading manufacturers, and identifies emerging opportunities within this expanding pharmaceutical sector.

Market Overview

The global Generic Nifedipine Controlled-release Tablets market is projected to experience significant growth from 2025 through 2032, expanding at a steady compound annual growth rate during the forecast period from 2026 to 2032.

Product Description

Nifedipine controlled-release tablets are a type of medication used primarily to treat high blood pressure (hypertension) and certain types of chest pain (angina). Nifedipine belongs to a class of drugs known as calcium channel blockers. These tablets are formulated to release the medication slowly over time, which helps maintain a steady level of the drug in the body and can prolong its therapeutic effect.

Regional Market Analysis

• United States: The market for Generic Nifedipine Controlled-release Tablets in the United States is estimated to increase from 2025 through 2032, growing at a consistent compound annual growth rate.
• China: The market for Generic Nifedipine Controlled-release Tablets in China is estimated to increase from 2025 through 2032, growing at a consistent compound annual growth rate.
• Europe: The market for Generic Nifedipine Controlled-release Tablets in Europe is estimated to increase from 2025 through 2032, growing at a consistent compound annual growth rate.

Market Segmentation

By Type

• 30mg per Tablet
• 60mg per Tablet

By Application

• Hypertension
• Exertional Angina
• Other

By Region

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

Competitive Landscape

Key Players

The following companies have been profiled based on primary expert input and analysis of their coverage, product portfolios, and market penetration:

• Shanghai Shyndec Pharma
• Simcere
• Qingdao Baiyang Pharmaceutical
• CR DOUBLE-CRANE
• Hefei Cube Pharma
• Deyao Pharma
• Apichope
• Nanjing Easeheal Pharma
• Beijing Honglin Pharma

Market Share and Competition

Global key players in the Generic Nifedipine Controlled-release Tablets market include Shanghai Shyndec Pharma, Simcere, Qingdao Baiyang Pharmaceutical, CR DOUBLE-CRANE, and Hefei Cube Pharma. In 2025, the two largest companies globally held a significant portion of the market share.

About the Report

LP Information, Inc. (LPI)'s newest research report, the “Generic Nifedipine Controlled-release Tablets Industry Forecast,” examines past sales and reviews total global Generic Nifedipine Controlled-release Tablets sales in 2025. It provides a comprehensive analysis of projected sales for 2026 through 2032, broken down by region, market sector, and sub-sector, presenting detailed analysis in US$ millions.

Scope and Methodology

This Insight Report provides a comprehensive analysis of the global Generic Nifedipine Controlled-release Tablets landscape, highlighting key trends related to:

• Product segmentation
• Company formation
• Revenue and market share
• Latest developments
• M&A activity

The report also analyzes the strategies of leading global companies, focusing on their Generic Nifedipine Controlled-release Tablets portfolios and capabilities, market entry strategies, market positions, and geographic footprints to understand their unique positions in an accelerating global market.

Furthermore, the report evaluates key market trends, drivers, and affecting factors shaping the global outlook. It breaks down the forecast by Type, Application, geography, and market size to highlight emerging pockets of opportunity. Utilizing a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study offers a highly nuanced view of the current state and future trajectory of the global Generic Nifedipine Controlled-release Tablets industry.

Key Questions Addressed

• What is the 10-year outlook for the global Generic Nifedipine Controlled-release Tablets market?
• What factors are driving Generic Nifedipine Controlled-release Tablets market growth, globally and by region?
• Which technologies are poised for the fastest growth by market and region?
• How do Generic Nifedipine Controlled-release Tablets market opportunities vary by end market size?
• How does Generic Nifedipine Controlled-release Tablets break out by Type and by Application?

• 1 Scope of the Report

  • 1.1 Market Introduction

  • 1.2 Years Considered

  • 1.3 Research Objectives

  • 1.4 Market Research Methodology

  • 1.5 Research Process and Data Source

  • 1.6 Economic Indicators

  • 1.7 Currency Considered

  • 1.8 Market Estimation Caveats

• 2 Executive Summary

  • 2.1 World Market Overview

    • 2.1.1 Global Generic Nifedipine Controlled-release Tablets Annual Sales 2021-2032

    • 2.1.2 World Current & Future Analysis for Generic Nifedipine Controlled-release Tablets by Geographic Region, 2021, 2025 & 2032

    • 2.1.3 World Current & Future Analysis for Generic Nifedipine Controlled-release Tablets by Country/Region, 2021, 2025 & 2032

  • 2.2 Generic Nifedipine Controlled-release Tablets Segment by Type

    • 2.2.1 30mg per Tablet

    • 2.2.2 60mg per Tablet

    • 2.2.3 Generic Nifedipine Controlled-release Tablets Sales by Type

      • 2.2.3.1 Global Generic Nifedipine Controlled-release Tablets Sales Market Share by Type (2021-2026)
      • 2.2.3.2 Global Generic Nifedipine Controlled-release Tablets Revenue and Market Share by Type (2021-2026)
      • 2.2.3.3 Global Generic Nifedipine Controlled-release Tablets Sale Price by Type (2021-2026)

  • 2.3 Generic Nifedipine Controlled-release Tablets Segment by Application

    • 2.3.1 Hypertension

    • 2.3.2 Exertional Angina

    • 2.3.3 Other

    • 2.3.4 Generic Nifedipine Controlled-release Tablets Sales by Application

      • 2.3.4.1 Global Generic Nifedipine Controlled-release Tablets Sale Market Share by Application (2021-2026)
      • 2.3.4.2 Global Generic Nifedipine Controlled-release Tablets Revenue and Market Share by Application (2021-2026)
      • 2.3.4.3 Global Generic Nifedipine Controlled-release Tablets Sale Price by Application (2021-2026)

• 3 Global by Company

  • 3.1 Global Generic Nifedipine Controlled-release Tablets Breakdown Data by Company

    • 3.1.1 Global Generic Nifedipine Controlled-release Tablets Annual Sales by Company (2021-2026)

    • 3.1.2 Global Generic Nifedipine Controlled-release Tablets Sales Market Share by Company (2021-2026)

  • 3.2 Global Generic Nifedipine Controlled-release Tablets Annual Revenue by Company (2021-2026)

    • 3.2.1 Global Generic Nifedipine Controlled-release Tablets Revenue by Company (2021-2026)

    • 3.2.2 Global Generic Nifedipine Controlled-release Tablets Revenue Market Share by Company (2021-2026)

  • 3.3 Global Generic Nifedipine Controlled-release Tablets Sale Price by Company

  • 3.4 Key Manufacturers Generic Nifedipine Controlled-release Tablets Producing Area Distribution, Sales Area, Product Type

    • 3.4.1 Key Manufacturers Generic Nifedipine Controlled-release Tablets Product Location Distribution

    • 3.4.2 Players Generic Nifedipine Controlled-release Tablets Products Offered

  • 3.5 Market Concentration Rate Analysis

    • 3.5.1 Competition Landscape Analysis

    • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

  • 3.6 New Products and Potential Entrants

  • 3.7 Market M&A Activity & Strategy

• 4 World Historic Review for Generic Nifedipine Controlled-release Tablets by Geographic Region

  • 4.1 World Historic Generic Nifedipine Controlled-release Tablets Market Size by Geographic Region (2021-2026)

    • 4.1.1 Global Generic Nifedipine Controlled-release Tablets Annual Sales by Geographic Region (2021-2026)

    • 4.1.2 Global Generic Nifedipine Controlled-release Tablets Annual Revenue by Geographic Region (2021-2026)

  • 4.2 World Historic Generic Nifedipine Controlled-release Tablets Market Size by Country/Region (2021-2026)

    • 4.2.1 Global Generic Nifedipine Controlled-release Tablets Annual Sales by Country/Region (2021-2026)

    • 4.2.2 Global Generic Nifedipine Controlled-release Tablets Annual Revenue by Country/Region (2021-2026)

  • 4.3 Americas Generic Nifedipine Controlled-release Tablets Sales Growth

  • 4.4 APAC Generic Nifedipine Controlled-release Tablets Sales Growth

  • 4.5 Europe Generic Nifedipine Controlled-release Tablets Sales Growth

  • 4.6 Middle East & Africa Generic Nifedipine Controlled-release Tablets Sales Growth

• 5 Americas

  • 5.1 Americas Generic Nifedipine Controlled-release Tablets Sales by Country

    • 5.1.1 Americas Generic Nifedipine Controlled-release Tablets Sales by Country (2021-2026)

    • 5.1.2 Americas Generic Nifedipine Controlled-release Tablets Revenue by Country (2021-2026)

  • 5.2 Americas Generic Nifedipine Controlled-release Tablets Sales by Type (2021-2026)

  • 5.3 Americas Generic Nifedipine Controlled-release Tablets Sales by Application (2021-2026)

  • 5.4 United States

  • 5.5 Canada

  • 5.6 Mexico

  • 5.7 Brazil

• 6 APAC

  • 6.1 APAC Generic Nifedipine Controlled-release Tablets Sales by Region

    • 6.1.1 APAC Generic Nifedipine Controlled-release Tablets Sales by Region (2021-2026)

    • 6.1.2 APAC Generic Nifedipine Controlled-release Tablets Revenue by Region (2021-2026)

  • 6.2 APAC Generic Nifedipine Controlled-release Tablets Sales by Type (2021-2026)

  • 6.3 APAC Generic Nifedipine Controlled-release Tablets Sales by Application (2021-2026)

  • 6.4 China

  • 6.5 Japan

  • 6.6 South Korea

  • 6.7 Southeast Asia

  • 6.8 India

  • 6.9 Australia

  • 6.10 China Taiwan

• 7 Europe

  • 7.1 Europe Generic Nifedipine Controlled-release Tablets by Country

    • 7.1.1 Europe Generic Nifedipine Controlled-release Tablets Sales by Country (2021-2026)

    • 7.1.2 Europe Generic Nifedipine Controlled-release Tablets Revenue by Country (2021-2026)

  • 7.2 Europe Generic Nifedipine Controlled-release Tablets Sales by Type (2021-2026)

  • 7.3 Europe Generic Nifedipine Controlled-release Tablets Sales by Application (2021-2026)

  • 7.4 Germany

  • 7.5 France

  • 7.6 UK

  • 7.7 Italy

  • 7.8 Russia

• 8 Middle East & Africa

  • 8.1 Middle East & Africa Generic Nifedipine Controlled-release Tablets by Country

    • 8.1.1 Middle East & Africa Generic Nifedipine Controlled-release Tablets Sales by Country (2021-2026)

    • 8.1.2 Middle East & Africa Generic Nifedipine Controlled-release Tablets Revenue by Country (2021-2026)

  • 8.2 Middle East & Africa Generic Nifedipine Controlled-release Tablets Sales by Type (2021-2026)

  • 8.3 Middle East & Africa Generic Nifedipine Controlled-release Tablets Sales by Application (2021-2026)

  • 8.4 Egypt

  • 8.5 South Africa

  • 8.6 Israel

  • 8.7 Turkey

  • 8.8 GCC Countries

• 9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers & Growth Opportunities

  • 9.2 Market Challenges & Risks

  • 9.3 Industry Trends

• 10 Manufacturing Cost Structure Analysis

  • 10.1 Raw Material and Suppliers

  • 10.2 Manufacturing Cost Structure Analysis of Generic Nifedipine Controlled-release Tablets

  • 10.3 Manufacturing Process Analysis of Generic Nifedipine Controlled-release Tablets

  • 10.4 Industry Chain Structure of Generic Nifedipine Controlled-release Tablets

• 11 Marketing, Distributors and Customer

  • 11.1 Sales Channel

    • 11.1.1 Direct Channels

    • 11.1.2 Indirect Channels

  • 11.2 Generic Nifedipine Controlled-release Tablets Distributors

  • 11.3 Generic Nifedipine Controlled-release Tablets Customer

• 12 World Forecast Review for Generic Nifedipine Controlled-release Tablets by Geographic Region

  • 12.1 Global Generic Nifedipine Controlled-release Tablets Market Size Forecast by Region

    • 12.1.1 Global Generic Nifedipine Controlled-release Tablets Forecast by Region (2027-2032)

    • 12.1.2 Global Generic Nifedipine Controlled-release Tablets Annual Revenue Forecast by Region (2027-2032)

  • 12.2 Americas Forecast by Country (2027-2032)

  • 12.3 APAC Forecast by Region (2027-2032)

  • 12.4 Europe Forecast by Country (2027-2032)

  • 12.5 Middle East & Africa Forecast by Country (2027-2032)

  • 12.6 Global Generic Nifedipine Controlled-release Tablets Forecast by Type (2027-2032)

  • 12.7 Global Generic Nifedipine Controlled-release Tablets Forecast by Application (2027-2032)

• 13 Key Players Analysis

  • 13.1 Shanghai Shyndec Pharma

    • 13.1.1 Shanghai Shyndec Pharma Company Information

    • 13.1.2 Shanghai Shyndec Pharma Generic Nifedipine Controlled-release Tablets Product Portfolios and Specifications

    • 13.1.3 Shanghai Shyndec Pharma Generic Nifedipine Controlled-release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.1.4 Shanghai Shyndec Pharma Main Business Overview

    • 13.1.5 Shanghai Shyndec Pharma Latest Developments

  • 13.2 Simcere

    • 13.2.1 Simcere Company Information

    • 13.2.2 Simcere Generic Nifedipine Controlled-release Tablets Product Portfolios and Specifications

    • 13.2.3 Simcere Generic Nifedipine Controlled-release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.2.4 Simcere Main Business Overview

    • 13.2.5 Simcere Latest Developments

  • 13.3 Qingdao Baiyang Pharmaceutical

    • 13.3.1 Qingdao Baiyang Pharmaceutical Company Information

    • 13.3.2 Qingdao Baiyang Pharmaceutical Generic Nifedipine Controlled-release Tablets Product Portfolios and Specifications

    • 13.3.3 Qingdao Baiyang Pharmaceutical Generic Nifedipine Controlled-release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.3.4 Qingdao Baiyang Pharmaceutical Main Business Overview

    • 13.3.5 Qingdao Baiyang Pharmaceutical Latest Developments

  • 13.4 CR DOUBLE-CRANE

    • 13.4.1 CR DOUBLE-CRANE Company Information

    • 13.4.2 CR DOUBLE-CRANE Generic Nifedipine Controlled-release Tablets Product Portfolios and Specifications

    • 13.4.3 CR DOUBLE-CRANE Generic Nifedipine Controlled-release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.4.4 CR DOUBLE-CRANE Main Business Overview

    • 13.4.5 CR DOUBLE-CRANE Latest Developments

  • 13.5 Hefei Cube Pharma

    • 13.5.1 Hefei Cube Pharma Company Information

    • 13.5.2 Hefei Cube Pharma Generic Nifedipine Controlled-release Tablets Product Portfolios and Specifications

    • 13.5.3 Hefei Cube Pharma Generic Nifedipine Controlled-release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.5.4 Hefei Cube Pharma Main Business Overview

    • 13.5.5 Hefei Cube Pharma Latest Developments

  • 13.6 Deyao Pharma

    • 13.6.1 Deyao Pharma Company Information

    • 13.6.2 Deyao Pharma Generic Nifedipine Controlled-release Tablets Product Portfolios and Specifications

    • 13.6.3 Deyao Pharma Generic Nifedipine Controlled-release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.6.4 Deyao Pharma Main Business Overview

    • 13.6.5 Deyao Pharma Latest Developments

  • 13.7 Apichope

    • 13.7.1 Apichope Company Information

    • 13.7.2 Apichope Generic Nifedipine Controlled-release Tablets Product Portfolios and Specifications

    • 13.7.3 Apichope Generic Nifedipine Controlled-release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.7.4 Apichope Main Business Overview

    • 13.7.5 Apichope Latest Developments

  • 13.8 Nanjing Easeheal Pharma

    • 13.8.1 Nanjing Easeheal Pharma Company Information

    • 13.8.2 Nanjing Easeheal Pharma Generic Nifedipine Controlled-release Tablets Product Portfolios and Specifications

    • 13.8.3 Nanjing Easeheal Pharma Generic Nifedipine Controlled-release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.8.4 Nanjing Easeheal Pharma Main Business Overview

    • 13.8.5 Nanjing Easeheal Pharma Latest Developments

  • 13.9 Beijing Honglin Pharma

    • 13.9.1 Beijing Honglin Pharma Company Information

    • 13.9.2 Beijing Honglin Pharma Generic Nifedipine Controlled-release Tablets Product Portfolios and Specifications

    • 13.9.3 Beijing Honglin Pharma Generic Nifedipine Controlled-release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.9.4 Beijing Honglin Pharma Main Business Overview

    • 13.9.5 Beijing Honglin Pharma Latest Developments

• 14 Research Findings and Conclusion